New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine
To determine the relative tolerability and efficacy of two newer antiepileptic drugs, lamotrigine (LTG) and gabapentin (GBP), as compared to carbamazepine (CBZ) in older patients with epilepsy. This was an 18-center, randomized, double-blind, double dummy, parallel study of 593 elderly subjects with...
Saved in:
Published in | Neurology Vol. 64; no. 11; p. 1868 |
---|---|
Main Authors | , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
14.06.2005
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | To determine the relative tolerability and efficacy of two newer antiepileptic drugs, lamotrigine (LTG) and gabapentin (GBP), as compared to carbamazepine (CBZ) in older patients with epilepsy.
This was an 18-center, randomized, double-blind, double dummy, parallel study of 593 elderly subjects with newly diagnosed seizures. Patients were randomly assigned to one of three treatment groups: GBP 1,500 mg/day, LTG 150 mg/day, CBZ 600 mg/day. The primary outcome measure was retention in trial for 12 months.
Mean age was 72 years. The most common etiology was cerebral infarction. Patients had multiple medical conditions and took an average of seven comedications. Mean plasma levels at 6 weeks were as follows: GBP 8.67 +/- 4.83 microg/mL, LTG 2.87 +/- 1.60 microg/mL, CBZ 6.79 +/- 2.92 microg/mL. They remained stable throughout the trial. Early terminations: LTG 44.2%, GBP 51%, CBZ 64.5% (p = 0.0002). Significant paired comparisons: LTG vs CBZ: p < 0.0001; GBP vs CBZ: p = 0.008. Terminations for adverse events: LTG 12.1%, GBP 21.6%, CBZ 31% (p = 0.001). Significant paired comparisons: LTG vs CBZ: p < 0.0001; LTG vs GBP: p = 0.015. There were no significant differences in seizure free rate at 12 months.
The main limiting factor in patient retention was adverse drug reactions. Patients taking lamotrigine (LTG) or gabapentin (GBP) did better than those taking carbamazepine. Seizure control was similar among groups. LTG and GBP should be considered as initial therapy for older patients with newly diagnosed seizures. |
---|---|
AbstractList | To determine the relative tolerability and efficacy of two newer antiepileptic drugs, lamotrigine (LTG) and gabapentin (GBP), as compared to carbamazepine (CBZ) in older patients with epilepsy.
This was an 18-center, randomized, double-blind, double dummy, parallel study of 593 elderly subjects with newly diagnosed seizures. Patients were randomly assigned to one of three treatment groups: GBP 1,500 mg/day, LTG 150 mg/day, CBZ 600 mg/day. The primary outcome measure was retention in trial for 12 months.
Mean age was 72 years. The most common etiology was cerebral infarction. Patients had multiple medical conditions and took an average of seven comedications. Mean plasma levels at 6 weeks were as follows: GBP 8.67 +/- 4.83 microg/mL, LTG 2.87 +/- 1.60 microg/mL, CBZ 6.79 +/- 2.92 microg/mL. They remained stable throughout the trial. Early terminations: LTG 44.2%, GBP 51%, CBZ 64.5% (p = 0.0002). Significant paired comparisons: LTG vs CBZ: p < 0.0001; GBP vs CBZ: p = 0.008. Terminations for adverse events: LTG 12.1%, GBP 21.6%, CBZ 31% (p = 0.001). Significant paired comparisons: LTG vs CBZ: p < 0.0001; LTG vs GBP: p = 0.015. There were no significant differences in seizure free rate at 12 months.
The main limiting factor in patient retention was adverse drug reactions. Patients taking lamotrigine (LTG) or gabapentin (GBP) did better than those taking carbamazepine. Seizure control was similar among groups. LTG and GBP should be considered as initial therapy for older patients with newly diagnosed seizures. |
Author | Ramsay, R E Spitz, M Marks, W Frederick, T Carter, G S Boardman, K D Felicetta, J Pryor, F Towne, A Uthman, B M Rowan, A J Collins, J F Tomyanovich, M L |
Author_xml | – sequence: 1 givenname: A J surname: Rowan fullname: Rowan, A J email: aj.rowan@med.va.gov organization: VA Medical Center, Bronx, NY 10468, USA. aj.rowan@med.va.gov – sequence: 2 givenname: R E surname: Ramsay fullname: Ramsay, R E – sequence: 3 givenname: J F surname: Collins fullname: Collins, J F – sequence: 4 givenname: F surname: Pryor fullname: Pryor, F – sequence: 5 givenname: K D surname: Boardman fullname: Boardman, K D – sequence: 6 givenname: B M surname: Uthman fullname: Uthman, B M – sequence: 7 givenname: M surname: Spitz fullname: Spitz, M – sequence: 8 givenname: T surname: Frederick fullname: Frederick, T – sequence: 9 givenname: A surname: Towne fullname: Towne, A – sequence: 10 givenname: G S surname: Carter fullname: Carter, G S – sequence: 11 givenname: W surname: Marks fullname: Marks, W – sequence: 12 givenname: J surname: Felicetta fullname: Felicetta, J – sequence: 13 givenname: M L surname: Tomyanovich fullname: Tomyanovich, M L |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/15955935$$D View this record in MEDLINE/PubMed |
BookMark | eNo1j11LwzAYhYMozk3_ggSv15qkzZd3MuYHjHmj6JXjbfJmRNa0tB2y_XoL6rk5N8954EzJaWoSEnLDWc4FF7eM5-_rVc7GcKULU-bKCKbzYnlCLrgUKlOF-JiQad9_jYgU2p6TCZdWSlvIC_K5xm_apB4HusUuwtBFR7GNO2z7wx0F2kHyTR2P6Gk_7P2BNoFuoYIW0xDTnO6gbsbRNiac05GlDroKajiOkoSX5CzArserv56Rt4fl6-IpW708Pi_uV5krSj1kGlgo0TjDSg_GC8O8NBrKyiiNXJsqCBWsktYb6b0OigWLyjruLDrnvZiR619vu69q9Ju2izV0h83_UfEDNnRZWw |
CitedBy_id | crossref_primary_10_1002_14651858_CD011922_pub4 crossref_primary_10_1016_j_ijge_2012_05_013 crossref_primary_10_1002_epi4_12239 crossref_primary_10_1016_j_archger_2024_105605 crossref_primary_10_1002_phar_1855 crossref_primary_10_1016_S1474_4422_20_30035_1 crossref_primary_10_17749_2077_8333_epi_par_con_2023_135 crossref_primary_10_1016_S0513_5117_08_70129_7 crossref_primary_10_2174_1570159X20666220507020635 crossref_primary_10_1111_epi_13448 crossref_primary_10_1016_j_neurol_2008_10_028 crossref_primary_10_1002_gps_1784 crossref_primary_10_1016_j_yebeh_2007_04_007 crossref_primary_10_3390_w13182539 crossref_primary_10_1017_S1748232106000061 crossref_primary_10_1016_j_heliyon_2024_e26376 crossref_primary_10_1007_s00115_011_3339_y crossref_primary_10_1016_j_eplepsyres_2024_107496 crossref_primary_10_1016_j_seizure_2010_05_008 crossref_primary_10_1016_j_jamda_2007_11_004 crossref_primary_10_1007_s15202_013_0426_x crossref_primary_10_1016_j_eplepsyres_2010_02_008 crossref_primary_10_1111_j_1399_5618_2011_00923_x crossref_primary_10_1111_j_1600_0404_2006_00748_x crossref_primary_10_1007_s00115_007_2328_7 crossref_primary_10_1016_j_mayocp_2016_11_013 crossref_primary_10_1097_WAD_0000000000000134 crossref_primary_10_1016_j_eplepsyres_2016_09_021 crossref_primary_10_1517_14740338_5_3_401 crossref_primary_10_1016_j_yebeh_2020_107540 crossref_primary_10_1111_epi_13675 crossref_primary_10_1002_phar_2012 crossref_primary_10_1177_2042098613505614 crossref_primary_10_1097_WCO_0000000000001143 crossref_primary_10_1212_CON_0000000000001521 crossref_primary_10_1590_S1676_26492009000200003 crossref_primary_10_1002_14651858_CD011922_pub3 crossref_primary_10_1002_14651858_CD011922_pub2 crossref_primary_10_1016_j_yebeh_2014_04_014 crossref_primary_10_1177_1533317518813551 crossref_primary_10_1007_s12151_007_0045_y crossref_primary_10_1007_s00115_007_2257_5 crossref_primary_10_1111_j_1755_5949_2011_00251_x crossref_primary_10_3233_JRS_235001 crossref_primary_10_1016_j_seizure_2018_08_001 crossref_primary_10_1097_FTD_0b013e31824d6a4e crossref_primary_10_1016_j_yebeh_2010_12_033 crossref_primary_10_1111_j_1528_1167_2008_01447_x crossref_primary_10_1097_01_wco_0000218239_90711_bd crossref_primary_10_1002_14651858_CD001031_pub4 crossref_primary_10_1177_0883073807303253 crossref_primary_10_1002_14651858_CD001031_pub3 crossref_primary_10_1111_epi_14519 crossref_primary_10_52667_2712_9179_2021_1_2_46_62 crossref_primary_10_17749_2077_8333_epi_par_con_2022_117 crossref_primary_10_1002_jppr_1135 crossref_primary_10_1016_j_lfs_2018_01_021 crossref_primary_10_3988_jcn_2020_16_4_556 crossref_primary_10_1016_j_seizure_2007_01_004 crossref_primary_10_1016_j_yebeh_2014_03_008 crossref_primary_10_1007_s12612_009_0018_8 crossref_primary_10_1038_nrneurol_2009_74 crossref_primary_10_1111_epi_16366 crossref_primary_10_1212_01_CON_0000368235_64857_cf crossref_primary_10_7759_cureus_30195 crossref_primary_10_1016_S1474_4422_07_70115_1 crossref_primary_10_1016_j_yebeh_2015_03_027 crossref_primary_10_1136_bcr_2012_006881 crossref_primary_10_1016_j_neurol_2011_10_012 crossref_primary_10_1016_j_seizure_2013_06_005 crossref_primary_10_1097_01_nrl_0000256353_14257_7c crossref_primary_10_1007_s15005_015_1378_9 crossref_primary_10_1111_j_1528_1167_2007_01128_x crossref_primary_10_1345_aph_1L305 crossref_primary_10_1016_j_jstrokecerebrovasdis_2014_07_050 crossref_primary_10_1007_s00115_008_2638_4 crossref_primary_10_1177_0091270007313391 crossref_primary_10_1007_s11940_022_00740_5 crossref_primary_10_1111_ane_13312 crossref_primary_10_1007_s40266_018_0562_2 crossref_primary_10_1186_s12883_016_0663_7 crossref_primary_10_1093_ijpp_riae055 crossref_primary_10_1590_0004_282x_anp_2020_0012 crossref_primary_10_1007_s11940_008_0026_9 crossref_primary_10_1016_j_yebeh_2005_05_003 crossref_primary_10_1016_S1634_7072_20_43686_4 crossref_primary_10_1007_s10309_022_00492_x crossref_primary_10_1007_s11910_016_0696_8 crossref_primary_10_2220_biomedres_38_297 crossref_primary_10_1001_jamaneurol_2018_1935 crossref_primary_10_1007_s10309_014_0385_z crossref_primary_10_1097_01720610_200702000_00016 crossref_primary_10_4137_CMT_S2165 crossref_primary_10_1016_j_seizure_2015_06_016 crossref_primary_10_1016_j_seizure_2017_04_010 crossref_primary_10_1007_s40266_022_00998_z crossref_primary_10_1111_j_1535_7511_2007_00198_x crossref_primary_10_1002_ana_22439 crossref_primary_10_1016_j_eplepsyres_2005_09_031 crossref_primary_10_1021_acs_orglett_9b00655 crossref_primary_10_1007_s11936_013_0236_7 crossref_primary_10_1212_WNL_64_11_1834 crossref_primary_10_2165_00003495_200666130_00004 crossref_primary_10_1017_S0959259808002694 crossref_primary_10_1111_j_1528_1167_2012_03640_x crossref_primary_10_1016_S1634_7072_21_44998_6 crossref_primary_10_1111_j_1528_1167_2008_01892_x crossref_primary_10_18231_j_ijn_2022_005 crossref_primary_10_1007_s42451_019_00135_y crossref_primary_10_1016_j_eplepsyres_2016_08_018 crossref_primary_10_2217_1745509X_3_4_509 crossref_primary_10_1016_S1474_4422_12_70105_9 crossref_primary_10_1016_j_eplepsyres_2005_09_018 crossref_primary_10_2165_00002512_200623110_00002 crossref_primary_10_1016_j_jns_2018_09_026 crossref_primary_10_1017_S1092852900027632 crossref_primary_10_1111_j_1528_1167_2008_01584_x crossref_primary_10_1016_j_annemergmed_2024_01_033 crossref_primary_10_1111_j_1528_1167_2008_01561_x crossref_primary_10_1016_j_nrl_2014_08_002 crossref_primary_10_1016_j_eplepsyres_2013_08_009 crossref_primary_10_1016_j_eplepsyres_2005_09_020 crossref_primary_10_1212_WNL_0b013e3182477edc crossref_primary_10_1016_j_neurobiolaging_2014_06_009 crossref_primary_10_1016_j_yebeh_2024_109913 crossref_primary_10_1016_j_yebeh_2005_11_007 crossref_primary_10_1016_j_ejpb_2014_12_027 crossref_primary_10_1016_j_eplepsyres_2016_08_023 crossref_primary_10_1212_01_wnl_0000261917_83337_db crossref_primary_10_3389_fneur_2018_00995 crossref_primary_10_1007_s10309_009_0033_1 crossref_primary_10_1007_s12028_007_0042_8 crossref_primary_10_1111_ene_12766 crossref_primary_10_1111_epi_17426 crossref_primary_10_1016_j_yebeh_2019_106724 crossref_primary_10_1111_ane_12162 crossref_primary_10_1007_s10309_022_00491_y crossref_primary_10_2217_1745509X_1_1_147 crossref_primary_10_3233_JAD_220983 crossref_primary_10_1016_S0246_0378_12_70007_6 crossref_primary_10_1080_14656566_2018_1496237 crossref_primary_10_1111_j_1528_1167_2006_00664_x crossref_primary_10_1002_14651858_CD011412_pub4 crossref_primary_10_1002_epi4_3 crossref_primary_10_1016_j_yebeh_2008_01_003 crossref_primary_10_1016_j_ncl_2011_07_001 crossref_primary_10_1016_S0211_3449_07_75454_1 crossref_primary_10_1002_14651858_CD011412_pub3 crossref_primary_10_1016_j_yebeh_2007_09_003 crossref_primary_10_1002_14651858_CD011412_pub2 crossref_primary_10_1016_j_yebeh_2009_10_019 crossref_primary_10_2217_ahe_09_88 crossref_primary_10_1007_s10309_014_0383_1 crossref_primary_10_1001_jamaneurol_2021_2249 crossref_primary_10_1016_j_mcna_2018_10_002 crossref_primary_10_1590_0004_282X20140151 crossref_primary_10_1111_j_1600_0404_2008_01018_x crossref_primary_10_1002_14651858_CD005398_pub3 crossref_primary_10_1111_j_1528_1167_2009_02069_x crossref_primary_10_3390_ijms241612639 crossref_primary_10_1016_S1474_4422_09_70240_6 crossref_primary_10_3805_eands_15_104 crossref_primary_10_1002_14651858_CD005398_pub4 crossref_primary_10_1212_WNL_0b013e3181d25b34 crossref_primary_10_5698_1535_7511_12_6_225 crossref_primary_10_1016_S0140_6736_06_68477_8 crossref_primary_10_4158_EP12119_OR crossref_primary_10_1080_14737175_2023_2278487 crossref_primary_10_1016_S0140_6736_07_60460_7 crossref_primary_10_2165_0002512_200926020_00007 crossref_primary_10_1111_epi_13853 crossref_primary_10_1016_S1474_4422_17_30044_3 crossref_primary_10_1517_14656560902772328 crossref_primary_10_4140_TCP_sA_2009_001 crossref_primary_10_1016_j_eplepsyres_2015_02_018 crossref_primary_10_1212_CON_0000000000001104 crossref_primary_10_1007_s10309_024_00733_1 crossref_primary_10_1212_CPJ_0b013e31823d07d1 crossref_primary_10_1016_S1634_7072_12_62057_1 crossref_primary_10_1007_s11940_014_0295_4 crossref_primary_10_1212_WNL_67_12_suppl_4_S3 crossref_primary_10_2176_nmc_ra_2015_0344 crossref_primary_10_3390_ph3092956 crossref_primary_10_1007_s40266_017_0465_7 crossref_primary_10_1002_epi4_12996 crossref_primary_10_1007_s40266_021_00837_7 crossref_primary_10_1016_j_ncl_2015_11_007 crossref_primary_10_1212_WNL_0000000000007010 crossref_primary_10_1111_epi_12074 crossref_primary_10_1111_epi_14010 crossref_primary_10_1177_2042098612455357 crossref_primary_10_1016_j_amjmed_2021_01_038 crossref_primary_10_1111_j_1600_0404_2005_00508_x crossref_primary_10_5698_1535_7597_18_4_260 crossref_primary_10_1016_j_eplepsyres_2007_04_009 crossref_primary_10_1016_j_nrleng_2014_08_002 crossref_primary_10_1586_14737175_6_11_1609 crossref_primary_10_1016_j_praneu_2011_09_001 crossref_primary_10_1016_j_yebeh_2023_109159 crossref_primary_10_1080_14737175_2017_1243469 crossref_primary_10_1517_17425255_2012_645535 crossref_primary_10_1007_s10309_008_0308_y crossref_primary_10_35615_epilia_2020_00143 crossref_primary_10_1111_bcp_13653 crossref_primary_10_36150_2499_6564_334 crossref_primary_10_1016_j_yebeh_2008_12_006 crossref_primary_10_3389_fneur_2022_855498 crossref_primary_10_1177_1533317508319433 crossref_primary_10_1016_j_eplepsyres_2006_10_008 crossref_primary_10_1212_WNL_0000000000005755 crossref_primary_10_1016_j_eplepsyres_2017_10_021 crossref_primary_10_1016_j_seizure_2017_05_002 crossref_primary_10_1002_jac5_1123 crossref_primary_10_1007_s12151_007_0059_5 crossref_primary_10_1016_j_seizure_2018_11_013 crossref_primary_10_1111_epi_17516 crossref_primary_10_1007_s13760_012_0070_9 crossref_primary_10_2217_1745509X_2_4_599 crossref_primary_10_1007_s13670_014_0078_5 crossref_primary_10_3805_eands_3_24 crossref_primary_10_1111_j_1600_0404_2010_01440_x crossref_primary_10_1016_S1474_4422_11_70047_3 crossref_primary_10_1016_j_regg_2009_05_010 crossref_primary_10_1016_j_neuroscience_2014_11_051 crossref_primary_10_1212_01_wnl_0000345667_45642_61 crossref_primary_10_1016_j_eplepsyres_2006_10_011 crossref_primary_10_1212_01_WNL_0000291947_29643_9f crossref_primary_10_2165_11631540_000000000_00000 crossref_primary_10_1161_STROKEAHA_120_033299 crossref_primary_10_1016_j_regg_2019_02_003 crossref_primary_10_1111_ane_12529 crossref_primary_10_1016_j_ijpharm_2016_01_001 crossref_primary_10_1007_s13760_019_01132_4 crossref_primary_10_1212_CON_0000000000000715 crossref_primary_10_1111_j_1528_1167_2007_01123_x crossref_primary_10_1016_j_yebeh_2012_11_041 crossref_primary_10_1016_j_eplepsyres_2007_08_004 crossref_primary_10_1016_j_eplepsyres_2021_106829 crossref_primary_10_1177_15357597241253505 crossref_primary_10_1007_s40120_019_0137_0 crossref_primary_10_1097_NRL_0b013e31815c613d crossref_primary_10_1177_15357597211015659 crossref_primary_10_3233_ADR_200286 crossref_primary_10_1007_s11065_007_9043_9 crossref_primary_10_1016_j_eplepsyres_2014_04_009 crossref_primary_10_1007_s13670_018_0235_3 crossref_primary_10_14581_jer_19003 crossref_primary_10_1016_j_eplepsyres_2008_03_022 crossref_primary_10_1016_j_neurol_2017_03_028 crossref_primary_10_1111_psyg_12463 crossref_primary_10_1007_s15014_014_0377_5 crossref_primary_10_1212_01_wnl_0000252941_50833_4a crossref_primary_10_1016_j_mcna_2006_06_002 crossref_primary_10_1586_14737175_6_12_1801 crossref_primary_10_1111_j_1749_6632_2009_05113_x crossref_primary_10_1016_j_seizure_2010_12_015 crossref_primary_10_1586_ern_10_170 crossref_primary_10_5698_1535_7511_11_1_9 crossref_primary_10_5698_1535_7511_13_1_22 crossref_primary_10_1111_j_1600_0404_2010_01464_x crossref_primary_10_1007_s10309_021_00442_z crossref_primary_10_1089_jpm_2006_9_24 crossref_primary_10_1007_s10309_013_0307_5 crossref_primary_10_1007_s00108_014_3467_0 crossref_primary_10_1007_s00415_013_7058_0 crossref_primary_10_1111_j_1600_0404_2006_00668_x crossref_primary_10_1093_advances_nmz047 crossref_primary_10_3238_arztebl_2009_0135 crossref_primary_10_1007_s11940_022_00744_1 crossref_primary_10_1002_pds_5139 crossref_primary_10_1111_jgs_13807 crossref_primary_10_5698_1535_7511_12_5_184 crossref_primary_10_1212_WNL_0b013e3181cbcd5c crossref_primary_10_1007_s13365_011_0074_x crossref_primary_10_1016_j_eplepsyres_2006_03_004 crossref_primary_10_1212_01_wnl_0000316392_55784_57 crossref_primary_10_1016_j_yebeh_2009_02_030 crossref_primary_10_1080_14656566_2020_1843636 crossref_primary_10_1007_s11910_008_0049_3 crossref_primary_10_1007_s15016_012_0514_8 crossref_primary_10_1016_j_neuarg_2013_03_001 crossref_primary_10_1097_MLR_0000000000001072 crossref_primary_10_1177_2042098611411127 crossref_primary_10_1097_01_wco_0000218235_67840_82 crossref_primary_10_1136_pgmj_2009_082883 crossref_primary_10_1038_ncpneuro0557 crossref_primary_10_1093_nop_npu010 crossref_primary_10_1016_j_eplepsyres_2005_07_019 crossref_primary_10_1586_14737175_8_6_929 crossref_primary_10_1517_14740338_2015_1088001 crossref_primary_10_1016_j_ncl_2009_06_007 crossref_primary_10_1016_S0513_5117_08_70029_2 crossref_primary_10_1111_epi_16068 crossref_primary_10_1007_s10309_009_0042_0 crossref_primary_10_1155_2012_641323 crossref_primary_10_5698_1535_7511_15_5_255 crossref_primary_10_1007_s00115_009_2680_x crossref_primary_10_1007_s11940_015_0342_9 crossref_primary_10_1080_14656566_2019_1618272 crossref_primary_10_1016_j_seizure_2017_02_006 crossref_primary_10_1016_j_ncl_2016_04_004 crossref_primary_10_1017_S0959259815000052 crossref_primary_10_1016_j_ncl_2006_01_001 crossref_primary_10_1517_14740338_2012_677026 crossref_primary_10_1177_15333175241303569 crossref_primary_10_3805_jjes_28_17 crossref_primary_10_5698_1535_7511_12_1_24 crossref_primary_10_1016_j_amjopharm_2007_06_001 crossref_primary_10_1016_j_amjopharm_2010_02_003 crossref_primary_10_1007_s11910_010_0120_8 crossref_primary_10_1212_WNL_0000000000200779 crossref_primary_10_1177_17562864211037430 crossref_primary_10_1111_epi_16616 crossref_primary_10_1016_j_yebeh_2009_01_005 crossref_primary_10_1016_j_seizure_2006_02_002 crossref_primary_10_1212_01_wnl_0000313157_15089_e6 crossref_primary_10_1016_j_yebeh_2011_04_005 crossref_primary_10_1111_j_1528_1167_2006_00585_x crossref_primary_10_1177_1756285609351945 crossref_primary_10_1097_WNF_0000000000000174 crossref_primary_10_1212_01_CON_0000431382_06438_cd crossref_primary_10_1007_s10309_008_0292_2 crossref_primary_10_1080_14656566_2020_1865311 crossref_primary_10_1186_s13256_023_03912_2 crossref_primary_10_1016_j_seizure_2008_06_003 crossref_primary_10_1111_epi_17494 crossref_primary_10_1080_14656566_2018_1549543 crossref_primary_10_1097_00132985_200605020_00012 crossref_primary_10_1111_j_1528_1167_2009_02235_x crossref_primary_10_1016_j_yebeh_2010_07_016 crossref_primary_10_1111_epi_16721 crossref_primary_10_1345_aph_1P385 crossref_primary_10_12659_MSM_894365 crossref_primary_10_1002_npr2_12196 crossref_primary_10_1007_s00228_011_1051_2 crossref_primary_10_1111_epi_12926 crossref_primary_10_2165_00023210_200822110_00003 crossref_primary_10_1097_WCO_0b013e3282f827f9 |
ContentType | Journal Article |
CorporateAuthor | VA Cooperative Study 428 Group |
CorporateAuthor_xml | – name: VA Cooperative Study 428 Group |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1212/01.WNL.0000167384.68207.3E |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1526-632X |
ExternalDocumentID | 15955935 |
Genre | Research Support, U.S. Gov't, Non-P.H.S Multicenter Study Comparative Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
GeographicLocations | United States |
GeographicLocations_xml | – name: United States |
GroupedDBID | --- -~X .55 .GJ .XZ .Z2 01R 0R~ 123 1J1 1KJ 354 3PY 4Q1 4Q2 4Q3 53G 5RE 5VS 6PF 77Y AAAXR AAGIX AAHPQ AAIQE AAJCS AAMOA AAMTA AAQKA AARTV AASCR AASOK AASXQ AAWTL AAXQO AAYEP AAYOK ABBLC ABIVO ABJNI ABOCM ABVCZ ACCJW ACDDN ACGFS ACIJW ACILI ACLDA ACOAL ACWRI ACXJB ADGGA ADNKB AE6 AEBDS AENEX AFDTB AFEXH AFFNX AFUWQ AGINI AHOMT AHQNM AHVBC AIJEX AJCLO AKCTQ AKULP AKWKN ALMA_UNASSIGNED_HOLDINGS AMJPA AMKUR AMNEI AOHHW AWKKM BOYCO BQLVK BYPQX C45 CGR CS3 CUY CVF DIWNM DU5 E.X EBS ECM EIF EJD ERAAH EX3 F2K F2L F2M F2N F5P FCALG FW0 GQDEL HZ~ H~9 IKYAY IN~ J5H JF7 KD2 KMI L-C L7B N4W N9A NEJ NPM N~7 N~B O9- OAG OAH OBH ODMTH OHH OHT OHYEH OJAPA OL1 OLB OLH OLU OLV OLW OLY OLZ OPX OVD OVDNE OVIDH OVLEI OWU OWV OWW OWX OWY OWZ OXXIT P2P RHI RLZ RXW SJN TEORI V2I VVN VXZ W3M WH7 WOQ WOW X7M XJT XOL XSW XXN XYM XYN YBU YCJ YFH ZKB ~9M |
ID | FETCH-LOGICAL-c347t-7a0f4e8c804da8d280d587a4b867e178bf26f9659d85dd7f60f9e69c1c9eccdd2 |
IngestDate | Wed Feb 19 01:41:43 EST 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 11 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c347t-7a0f4e8c804da8d280d587a4b867e178bf26f9659d85dd7f60f9e69c1c9eccdd2 |
PMID | 15955935 |
ParticipantIDs | pubmed_primary_15955935 |
PublicationCentury | 2000 |
PublicationDate | 2005-06-14 |
PublicationDateYYYYMMDD | 2005-06-14 |
PublicationDate_xml | – month: 06 year: 2005 text: 2005-06-14 day: 14 |
PublicationDecade | 2000 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Neurology |
PublicationTitleAlternate | Neurology |
PublicationYear | 2005 |
References | 16477322 - Epilepsy Curr. 2006 Jan-Feb;6(1):27-9 16388556 - ACP J Club. 2006 Jan-Feb;144(1):6 15955930 - Neurology. 2005 Jun 14;64(11):1834-5 |
References_xml | – reference: 16477322 - Epilepsy Curr. 2006 Jan-Feb;6(1):27-9 – reference: 15955930 - Neurology. 2005 Jun 14;64(11):1834-5 – reference: 16388556 - ACP J Club. 2006 Jan-Feb;144(1):6 |
SSID | ssj0015279 |
Score | 2.3844006 |
Snippet | To determine the relative tolerability and efficacy of two newer antiepileptic drugs, lamotrigine (LTG) and gabapentin (GBP), as compared to carbamazepine... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 1868 |
SubjectTerms | Aged Aging - physiology Amines - administration & dosage Amines - adverse effects Amines - blood Anticonvulsants - administration & dosage Anticonvulsants - adverse effects Anticonvulsants - blood Carbamazepine - administration & dosage Carbamazepine - adverse effects Carbamazepine - blood Cerebral Infarction - complications Cyclohexanecarboxylic Acids - administration & dosage Cyclohexanecarboxylic Acids - adverse effects Cyclohexanecarboxylic Acids - blood Dose-Response Relationship, Drug Double-Blind Method Epilepsy - drug therapy Epilepsy - epidemiology Epilepsy - etiology gamma-Aminobutyric Acid - administration & dosage gamma-Aminobutyric Acid - adverse effects gamma-Aminobutyric Acid - blood Hospitals, Veterans - statistics & numerical data Humans Patient Compliance - statistics & numerical data Patient Selection Treatment Outcome Triazines - administration & dosage Triazines - adverse effects Triazines - blood United States United States Department of Veterans Affairs - statistics & numerical data |
Title | New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine |
URI | https://www.ncbi.nlm.nih.gov/pubmed/15955935 |
Volume | 64 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8QwEA6rgngR32_JwZt27XaTJvUmooioiCh6UtI8Fg-7LW5B3F_vJGm3XVFRL6U0u2nJfJlMJjPfILRHKSMqYWkASwENSBRpuEt1EEZCS2vCGpf1fnUdn9-Ti0f62Gq9NbNLirQtR1_mlfxHqvAM5GqzZP8g2XGn8ADuQb5wBQnD9VcytsGJNhq62O_Z11my_X2dwzzPh-8-ixlWIpX1X0ZgVg4r-uieSEVug4ScwgFEZIWrjqWrSE5pzyD6YgRdDSYihRyTR9MNf5u9eQfqcX28dCv6Q-FF10hzcNzfHjN1MPHN67v3FpxNOB-oDZLySZ9tXSrMKA7iriuJPtaonpe8Qk6noR8tOf-XihtWUJeM0H64vnSckh1bjpS0Y25dYN3T5p9gAPO-EynYYgAnz3fyc-snUu2qaQpNwfbC1ku1Tp7y8IlGLCn5aeGzDr__KFfTyXf0aVfirJO7BTRfbivwscfIImrpwRKavSoDJ5bRE0AFO6jgMVRwBZUjLHANFOyAgjODa6Ac4AZMDjD8Fk-AZAXdn53enZwHZWmNQHYJKwImQkM0lzwkSnAV8VBRzgRJecx0h_HURLGxXJOKU6WYiUOT6DiRHZnAnFcqWkXTg2yg1xGmSjKjFVh6whAjiaBgRHOwIrmBRd2IDbTmR-Y59_wpz9WYbX7bsoXmarRtoxkDE1bvgPVXpLtOVh-KH1a3 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=New+onset+geriatric+epilepsy%3A+a+randomized+study+of+gabapentin%2C+lamotrigine%2C+and+carbamazepine&rft.jtitle=Neurology&rft.au=Rowan%2C+A+J&rft.au=Ramsay%2C+R+E&rft.au=Collins%2C+J+F&rft.au=Pryor%2C+F&rft.date=2005-06-14&rft.eissn=1526-632X&rft.volume=64&rft.issue=11&rft.spage=1868&rft_id=info:doi/10.1212%2F01.WNL.0000167384.68207.3E&rft_id=info%3Apmid%2F15955935&rft_id=info%3Apmid%2F15955935&rft.externalDocID=15955935 |